Axl of evil

Journal of Investigative Dermatology

Volumn 131, Issue 12, 2011, Pages 2343-2345

  Aplin, Andrew E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH ARREST SPECIFIC PROTEIN 6; NRAS PROTEIN; PROTEIN KINASE AXL; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VEMURAFENIB;

AUTOCRINE EFFECT; CANCER INVASION; HUMAN; MELANOMA; MELANOMA CELL; METASTASIS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR DIFFERENTIATION;

EID: 80855133583     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.308     Document Type: Note

References (10)

1. Goodall J, Carreira S, Denat L et al. (2008) Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res 68:7788-94
2. Hoek KS, Eichhoff OM, Schlegel NC et al. (2008) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68:650-6 (Pubitemid 351206739)
3. Holland SJ, Pan A, Franci C et al. (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70:1544-54
4. Johannessen CM, Boehm JS, Kim SY et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-72
5. Liu E, Hjelle B, Bishop JM (1988) Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci USA 85:1952-6 (Pubitemid 24315802)
6. O'Bryan JP, Frye RA, Cogswell PC et al. (1991) Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11:5016-31 (Pubitemid 21895263)
7. Sensi M, Catani M, Castellano G et al. (2011) Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol 131:2448-57
8. Tworkoski K, Singhal G, Szpakowski S et al. (2011) Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res 9:801-12
9. Villanueva J, Vultur A, Lee JT et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-95
10. Widlund HR, Fisher DE (2003) Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 22:3035-41 (Pubitemid 36713753)